- Home
- NYXH vs HURA Comparison
NYXH vs HURA Comparison
Compare NYXH & HURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NYXH | HURA |
|---|---|---|
| Founded | 2009 | 2009 |
| Country | Belgium | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 165.0M | 160.5M |
| IPO Year | 2021 | 2010 |
Fundamental Metrics
Financial Performance| Metric | NYXH | HURA |
|---|---|---|
| Price | $1.35 | $1.99 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 4 |
| Target Price | $4.26 | ★ $8.04 |
| AVG Volume (30 Days) | ★ 301.9K | 181.3K |
| Earning Date | 11-05-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 47.93 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $275.91 | N/A |
| Revenue Next Year | $93.27 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.26 | $0.41 |
| 52 Week High | $6.87 | $3.43 |
Technical Indicators
Market Signals| Indicator | NYXH | HURA |
|---|---|---|
| Relative Strength Index (RSI) | 43.89 | 49.24 |
| Support Level | $1.28 | $2.04 |
| Resistance Level | $1.70 | $2.23 |
| Average True Range (ATR) | 0.07 | 0.09 |
| MACD | -0.01 | 0.01 |
| Stochastic Oscillator | 27.51 | 48.33 |
Price Performance
Historical ComparisonAbout NYXH Nyxoah SA
Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.
About HURA TuHURA Biosciences Inc.
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.